Sponsor Pipeline

Aurinia Pharmaceuticals Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
2
Recruiting
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-04 NCT07596901
Study of Aritinercept in Patients With Generalized Myasthenia Gravis		 Trial sites expanded: 3 -> 11 locations
2026-08-04 NCT07611214
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients…		 Trial sites expanded: 15 -> 27 locations
Active Trials by Phase
Phase 4
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07611214 PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients… Lupus Nephritis Recruiting
Phase 1/2
NCT07596901 Study of Aritinercept in Patients With Generalized Myasthenia Gravis Myasthenia Gravis, Generalized Recruiting
Disease Areas
Myasthenia Gravis (1) Lupus (SLE) (1)
Get alerts when Aurinia Pharmaceuticals Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free